NF-κB in the New Era of Cancer Therapy

Baptiste Eluard1, Catherine Thieblemont2, Véronique Baud1

  • 1Université de Paris, NF-κB, Différenciation et Cancer, F-75006 Paris, France.

Trends in Cancer
|May 16, 2020
PubMed

Insights

New cancer vulnerabilities linked to NF-κB signaling offer therapeutic potential. Targeting these pathways and reprogramming metabolism may improve patient outcomes in the new era of cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Despite declining mortality, most cancers remain incurable, presenting a significant medical challenge.
  • Recent advances in cancer genetics and genomics have identified new cancer hallmarks, including metabolic reprogramming and immune evasion.

Purpose of the Study:

  • To review the therapeutic potential of Nuclear Factor kappa B (NF-κB) transcription factors in cancer.
  • To explore signaling pathways controlling NF-κB activity in the context of novel cancer hallmarks and therapies.

Main Methods:

  • Literature review of recent progress in cancer genetics, genomics, and immunology.
  • Analysis of NF-κB-dependent vulnerabilities and their role in cancer hallmarks.
  • Examination of therapeutic strategies involving NF-κB modulation and cutting-edge cancer treatments.

Main Results:

  • Identification of novel NF-κB-dependent cancer vulnerabilities associated with energy metabolism and immune evasion.
  • Demonstration of improved patient stratification based on these discoveries.
  • Emergence of new drug combinations utilizing cutting-edge therapies targeting NF-κB pathways.

Conclusions:

  • NF-κB transcription factors and their regulatory pathways represent promising therapeutic targets in oncology.
  • Targeting NF-κB offers potential for improved patient stratification and novel combination therapies.
  • This review provides an updated perspective on leveraging NF-κB in the evolving landscape of cancer treatment.

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
9.7K
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
8.3K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
374
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K